Source comparison
Melanotan-2 for Sunless Tanning: Mechanism Comparison
Melanotan-2 for sunless tanning represents a fundamentally different mechanism from topical self-tanners, UV tanning beds, and melanotan-1 analogs. The following comparison clarifies the distinctions across pigmentation modalities based on mechanism of action,
This comparison does not assign a generated winner or score.
- Melanotan-2 for sunless tanning represents a fundamentally different mechanism from topical self-tanners, UV tanning beds, and melanotan-1 analogs. The following comparison clarifies the distinctions across pigmentation modalities based on mechanism of action, onset timeline, pigment type, and regulatory status.
- Melanotan-2 (subcutaneous)
- MC1R and MC4R agonism → cAMP → tyrosinase upregulation → eumelanin synthesis
- 7–10 days (visible); 3–6 weeks (peak)
- Endogenous eumelanin (brown-black polymer)
- 4–8 weeks fade to baseline
- Unapproved investigational compound (FDA, EMA)
- Topical DHA self-tanner
- Non-enzymatic Maillard reaction between DHA and stratum corneum amino acids
- 4–6 hours (visible); 24 hours (peak)
- Melanoidin polymers (orange-brown dye)
- 5–7 days (shed with keratinocyte turnover)
- FDA-approved cosmetic (external use only)
- UV tanning bed (UVA-dominant)
- Direct DNA damage → p53 activation → MC1R signaling → delayed tanning response
- 24–72 hours (peak); cumulative over weeks
- Endogenous eumelanin + oxidized melanin
- 3–6 weeks fade to baseline
- FDA-regulated as Class I medical device
- Melanotan-1 (afamelanotide)
- Selective MC1R agonism → eumelanin synthesis (minimal MC4R activity)
- 7–14 days (visible); 4–8 weeks (peak)
- Endogenous eumelanin
- 6–10 weeks fade to baseline
- FDA-approved for erythropoietic protoporphyria (EPP); EU-approved for same
- Melanotan-2 for sunless tanning produces the same pigment type as UV exposure. Eumelanin. But without the photodamage, thymine dimer formation, or carcinogenic mutation accumulation that accompanies UV radiation. However, its non-selective receptor activity introduces systemic effects (nausea, appetite suppression, sexual arousal) absent in topical cosmetics or UV exposure. Melanotan-1, marketed as afamelanotide and sold under the brand name Scenesse, exhibits greater MC1R selectivity and minimal MC4R cross-reactivity, which eliminates most CNS-mediated side effects but requires higher doses and longer treatment durations to achieve equivalent pigmentation. Topical DHA produces pigmentation within hours but the color is distinctly orange-toned, fades rapidly, and provides no photoprotection. It's a cosmetic stain, not melanin.